News

Pfizer to Close Facility in Peapack, NJ, Affecting 781 Workers

1 Mins read

By Emon Reiser

Pfizer, a leading pharmaceutical company, will be closing its facility located in Peapack, N.J. This decision will have a substantial impact on the jobs of 781 workers, as reported in a Workers Adjustment and Retraining Notification filed with the state.

Workforce Reassignments

In an effort to mitigate the impact of the closure, Pfizer has announced that many of the affected employees will be reassigned to the company’s New York headquarters at 66 Hudson Yards. Additionally, a small number of workers will be moved to Pfizer’s Parsippany, N.J., site.

Planned Closure Date

The closure of the Peapack facility is scheduled to take place on February 12, 2024. This move comes after Pfizer’s announcement in 2021 that it intends to sell the entire Peapack campus.

Deliberation and Decision

Pfizer has been carefully considering the future of the Peapack site over the past couple of years. After extensive evaluation, the decision to close the facility has been made. As a result, Pfizer has informed its colleagues that all positions at the site will be relocating to other Pfizer facilities.

Impact of Workforce Cuts

Last month, Pfizer revealed workforce cuts as it revised its revenue guidance for the year. The company had to reduce its revenue projections by $9 billion due to a decline in sales of its Covid-19 vaccine.

Related posts
News

$TRUMP and other meme coins won't be protected by SEC, Commissioner Hester Peirce says

3 Mins read
LAS VEGAS — Now that the SEC is out of the business of regulating meme coins, investors shouldn’t expect any guidance on…
News

Man charged in New York with 3-week kidnapping to try to steal Bitcoin

1 Mins read
NEW YORK (Reuters) -A grand jury has indicted a 37-year-old cryptocurrency investor accused of kidnapping a business partner inManhattan’s upscale Soho neighborhood…
News

Goldman Sachs Expert Predicts Significant Gold Price Surge by 2026

2 Mins read
Investors are advised to consider risk-reward balance and portfolio diversification. Daan Struyven, co-head of global commodities research at Goldman Sachs, has projected…

Leave a Reply

Your email address will not be published. Required fields are marked *